Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-39148402

RESUMEN

INTRODUCTION: Congenital hypofibrinogenemia (CH) and congenital dysfibrinogenemia (CD) are rare coagulation disorders caused by quantitative or qualitative defects in the fibrinogen gene. The aim of this study was to characterize the genetic background and the clinical manifestations of congenital fibrinogen disorders in the patients from Slovakia registered at the National Haemophilia Centre. MATERIALS AND METHODS: Results of genetic analysis of the fibrinogen genes FGA, FGB and FGG using polymerase chain reaction followed by direct sequencing were evaluated in 36 patients. RESULTS: Molecular-genetic analysis revealed six novel variants - FGA c.923_968dup p.(Gly324Lysfs*44) and FGG c.1105C>T p.(His369Tyr) were identified in CD patients. In CH patients, in the FGG gene c.8G>A p.(Trp3*), c.823G>T p.(Glu275*) and c.323C>A p.(Ala108Asp) variants were detected. In the FGB gene c.1427C>T p.(Ser476Leu) was identified. CONCLUSION: This study is a positive contribution towards expanding knowledge about genetic variants in patients with congenital fibrinogen disorders.

2.
Birth Defects Res ; 116(4): e2342, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38632851

RESUMEN

BACKGROUND: Abortion and fetal death are common in fetuses with holoprosencephaly, so genetic examinations often have to be made in a post-mortem setting. The efficiency of the conventional karyotyping using cultured fibroblasts in these situations is limited due to frequent culture failure. In the current study, archived cases of holoprosencephaly, where post-mortem genetic evaluation was requested and sufficient frozen material was available, were reevaluated using the quantitative fluorescence polymerase chain reaction (QF-PCR) technique. METHODS: Testing for aneuploidies of chromosomes 13, 15, 16, 18, 21, 22, X, and Y with the QF-PCR technique was carried out on DNA isolated from archived frozen chorionic villi in seven cases of holoprosencephaly. RESULTS: QF-PCR was successful in all seven cases. Two cases of trisomy 13, two cases of triploidy, and one case of trisomy 18 was found meaning a 71% diagnostic yield. The success rate of QF-PCR (100%, 7/7) was superior compared to conventional karyotyping (43%, 3/7). CONCLUSIONS: Rapid aneuploidy testing using the QF-PCR technique is a simple, reliable, time- and cost-effective method sufficient to conclude the etiologic investigation in the majority of holoprosencephaly cases post-mortem.


Asunto(s)
Holoprosencefalia , Embarazo , Femenino , Humanos , Diagnóstico Prenatal/métodos , Aneuploidia , Reacción en Cadena de la Polimerasa/métodos , Cariotipificación
3.
Angew Chem Int Ed Engl ; 61(40): e202207175, 2022 10 04.
Artículo en Inglés | MEDLINE | ID: mdl-35876840

RESUMEN

2',3'-cGAMP is a cyclic A- and G-containing dinucleotide second messenger, which is formed upon cellular recognition of foreign cytosolic DNA as part of the innate immune response. The molecule binds to the adaptor protein STING, which induces an immune response characterized by the production of type I interferons and cytokines. The development of STING-binding molecules with both agonistic as well as antagonistic properties is currently of tremendous interest to induce or enhance antitumor or antiviral immunity on the one hand, or to treat autoimmune diseases on the other hand. To escape the host innate immune recognition, some viruses encode poxin endonucleases that cleave 2',3'-cGAMP. Here we report that dideoxy-2',3'-cGAMP (1) and analogs thereof, which lack the secondary ribose-OH groups, form a group of poxin-stable STING agonists. Despite their reduced affinity to STING, particularly the compound constructed from two A nucleosides, dideoxy-2',3'-cAAMP (2), features an unusually high antitumor response in mice.


Asunto(s)
Interferón Tipo I , Proteínas de la Membrana/genética , Nucleósidos , Animales , Antivirales , Citocinas , ADN , Endonucleasas , Inmunidad Innata , Proteínas de la Membrana/metabolismo , Ratones , Nucleótidos Cíclicos , Nucleotidiltransferasas/metabolismo , Ribosa
4.
Ortop Traumatol Rehabil ; 23(5): 335-339, 2021 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-34734566

RESUMEN

BACKGROUND: Developmental dysplasia of the hip (DDH) is a developmental disorder which is reported to be associated with hip instability. When untreated, it can lead to irreversible joint damage. DDH is known to be a multifactorial disease involving genetic, mechanical and environmental factors. The greatest causative potential is attributed to the genetic component. Growth Differentiation Factor 5 (GDF5) is among the most studied genes associated with processes of regeneration and maintenance of joints. The aim of this work was to analyse the association of SNP rs143383 in the GDF5 gene and the occurrence of DDH, along with association with various contributing factors in the Caucasian population. MATERIAL AND METHODS: A total of 118 samples were analysed for the presence of the mutation. DNA was isolated from all individuals from peripheral blood. SNP rs143383 in the GDF5 gene was genotyped using the TaqMan assay. A standard chi-square test was used to compare allele and genotype distributions in patients and healthy controls. RESULTS: The association analysis of genotypes of DDH and rs143383 revealed a significant association. Also, the association of GDF5 and selected contributing factors was statistically significant in female gender (p=0.002), family history (p<0.001), count of pregnancy (p=0.009), laterality of hip involvement and initial US examination. CONCLUSIONS: 1. The results indicate an important effect of rs143383 polymorphism in the GDF5 gene on DDH development. 2. However, our results also suggest that rs143383 is not the only contributing factor in the genetic component of DDH.


Asunto(s)
Displasia del Desarrollo de la Cadera , Luxación Congénita de la Cadera , Alelos , Femenino , Predisposición Genética a la Enfermedad , Factor 5 de Diferenciación de Crecimiento/genética , Luxación Congénita de la Cadera/epidemiología , Luxación Congénita de la Cadera/genética , Humanos , Lactante , Polimorfismo de Nucleótido Simple/genética
5.
Biotechniques ; 69(6): 427-435, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32967447

RESUMEN

Syncytin-1 (gene ERVW-1) has been proposed as a marker of pre-eclampsia and malfunctions in placental development. Placenta is heterogeneous tissue, hence the method of biopsy can significantly affect the outcome of analyses. A total of 44 placentae were analyzed by taking 3-30 samples from each. Relative levels of ERVW-1 expression in the placental biopsies were characterized by RT-qPCR. Evaluation of ten biopsies from one placenta individually (not pooling them) is recommended due to the high variability of expression. No significant correlation was found between biopsy localization and level of ERVW-1 expression; therefore, random sampling is recommended. A long cut from the umbilical cord to the edge of the placenta is a convenient approach to placental sampling.


Asunto(s)
Productos del Gen env/metabolismo , Placenta/metabolismo , Proteínas Gestacionales/metabolismo , Manejo de Especímenes , Adulto , Biopsia , Intervalos de Confianza , Femenino , Regulación de la Expresión Génica , Humanos , Placenta/patología , Embarazo , ARN/aislamiento & purificación
6.
J Immunother Cancer ; 7(1): 349, 2019 Dec 16.
Artículo en Inglés | MEDLINE | ID: mdl-31843014

RESUMEN

Following publication of the original article [1], the authors have reported that Fig. 2 and Additional file 1: Figure S1, S2 partially show red scripts.

7.
J Immunother Cancer ; 7(1): 288, 2019 11 06.
Artículo en Inglés | MEDLINE | ID: mdl-31694706

RESUMEN

BACKGROUND: The tumor microenvironment (TME) combines features of regulatory cytokines and immune cell populations to evade the recognition by the immune system. Myeloid-derived suppressor cells (MDSC) comprise populations of immature myeloid cells in tumor-bearing hosts with a highly immunosuppressive capacity. We could previously identify RIG-I-like helicases (RLH) as targets for the immunotherapy of pancreatic cancer inducing immunogenic tumor cell death and type I interferons (IFN) as key mediators linking innate with adaptive immunity. METHODS: Mice with orthotopically implanted KrasG12D p53fl/R172H Ptf1a-Cre (KPC) pancreatic tumors were treated intravenously with the RLH ligand polyinosinic-polycytidylic acid (poly(I:C)), and the immune cell environment in tumor and spleen was characterized. A comprehensive analysis of the suppressive capacity as well as the whole transcriptomic profile of isolated MDSC subsets was performed. Antigen presentation capability of MDSC from mice with ovalbumin (OVA)-expressing tumors was investigated in T cell proliferation assays. The role of IFN in MDSC function was investigated in Ifnar1-/- mice. RESULTS: MDSC were strongly induced in orthotopic KPC-derived pancreatic cancer, and frequencies of MDSC subsets correlated with tumor weight and G-CSF serum levels, whereas other immune cell populations decreased. Administration of the RLH-ligand induced a IFN-driven immune response, with increased activation of T cells and dendritic cells (DC), and a reduced suppressive capacity of both polymorphonuclear (PMN)-MDSC and monocytic (M)-MDSC fractions. Whole transcriptomic analysis confirmed an IFN-driven gene signature of MDSC, a switch from a M2/G2- towards a M1/G1-polarized phenotype, and the induction of genes involved in the antigen presentation machinery. Nevertheless, MDSC failed to present tumor antigen to T cells. Interestingly, we found MDSC with reduced suppressive function in Ifnar1-deficient hosts; however, there was a common flaw in immune cell activation, which was reflected by defective immune cell activation and tumor control. CONCLUSIONS: We provide evidence that the treatment with immunostimulatory RNA reprograms the TME of pancreatic cancer by reducing the suppressive activity of MDSC, polarizing myeloid cells into a M1-like state and recruiting DC. We postulate that tumor cell-targeting combination strategies may benefit from RLH-based TME remodeling. In addition, we provide novel insights into the dual role of IFN signaling in MDSC's suppressive function and provide evidence that host-intrinsic IFN signaling may be critical for MDSC to gain suppressive function during tumor development.

8.
Oncoimmunology ; 8(4): e1570779, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30906666

RESUMEN

Resistance to cell death and evasion of immunosurveillance are major causes of cancer persistence and progression. Tumor cell-intrinsic activation of the RNA receptor retinoic acid-inducible gene-I (RIG-I) can trigger an immunogenic form of programmed tumor cell death, but its impact on antitumor responses remains largely unexplored. We show that activation of intrinsic RIG-I signaling induces melanoma cell death that enforces cross-presentation of tumor-associated antigens by bystander dendritic cells. This results in systemic expansion and activation of tumor-antigen specific T cells in vivo with subsequent regression of pre-established melanoma. These processes were dependent on the signaling hub MAVS and type I interferon (IFN-I) signaling in the host cell. Using melanoma cells deficient for the transcription factors IRF3 and IRF7, we demonstrate that RIG-I-activated tumor cells used as a vaccine are a relevant source of IFN-I during T cell cross-priming in vivo. Thus, our findings may facilitate translational development of personalized anticancer vaccines.

9.
BMC Med Genet ; 19(1): 64, 2018 04 20.
Artículo en Inglés | MEDLINE | ID: mdl-29678161

RESUMEN

BACKGROUND: Short-chain acyl-CoA dehydrogenase deficiency (SCADD) represents a rare autosomal recessive inborn metabolic disorder of mitochondrial ß-oxidation of monocarboxylic acids. Clinical symptoms can vary from a severe life-threatening condition to an asymptomatic state, reported in the majority of cases. Since the expansion of newborn screenings, more than three hundred probands were admitted for molecular-genetic analysis, most selected because of elevated values of C4-acylcarnitine detected in newborn screenings in Slovakia. Searching for the principal genomic changes led us to the selection of sixty-two patients in whom the presence of sequence variants in the ACADS gene was analysed and correlated with the available biochemical and clinical data. METHODS: Biochemical and molecular genetic tests were performed. Acylcarnitine profiles focused on an elevated level of C4-acylcarnitine, which was analysed via tandem mass spectrometry. Urinary organic acids, specifically a quantity of ethylmalonic acid, were determined by gas chromatography/mass spectrometry. The entire coding region of the ACADS gene was sequenced. A low-cost restriction fragment length polymorphism of PCR amplified fragments analysis (PCR-RFLP) of pathogenic variants was introduced and implemented for the molecular-genetic algorithm appropriate for the Slovak population. RESULTS: Our molecular genetic study was performed on sixty-two patients with a pathological biochemical pattern related to short-chain acyl-CoA dehydrogenase deficiency. In this cohort, we discovered a high occurrence of two rare pathogenic variants-the deletion c.310_312delGAG and the substitution c.1138C>T, with allelic frequencies of 64% and 31%, respectively. Up to 86% of investigated individuals belong to the Roma ethnic group. CONCLUSIONS: Analogous to other countries, SCADD is not included in the newborn screening programme. Based on the exceeded levels of the specific biomarker C4-acylcarnitine as well as ethylmalonic acid, we revealed a high prevalence of short-chain acyl-CoA dehydrogenase deficiency cases, confirmed by the findings of two rare pathogenic variants. A deletion c.310_312delGAG and c.1138C > T substitution in the ACADS gene appear with a high frequency in the Roma ethnic group of Slovakia. Due to the uncertainty of the pathogenicity and clinical consequences, it is important to follow up the morbidity and mortality in these patients over time and evaluate SCADD in relation to clinical outcomes and preventive healthcare recommendations.


Asunto(s)
Acil-CoA Deshidrogenasa/deficiencia , Butiril-CoA Deshidrogenasa/genética , Carnitina/análogos & derivados , Etnicidad/genética , Errores Innatos del Metabolismo Lipídico/genética , Mutación , Acil-CoA Deshidrogenasa/genética , Acil-CoA Deshidrogenasa/metabolismo , Carnitina/metabolismo , Femenino , Frecuencia de los Genes , Pruebas Genéticas , Humanos , Recién Nacido , Errores Innatos del Metabolismo Lipídico/etnología , Errores Innatos del Metabolismo Lipídico/metabolismo , Masculino , Tamizaje Neonatal/métodos , Polimorfismo de Longitud del Fragmento de Restricción , Análisis de Secuencia de ADN , Eslovaquia/etnología
10.
BMC Med Genet ; 18(1): 59, 2017 05 31.
Artículo en Inglés | MEDLINE | ID: mdl-28569194

RESUMEN

BACKGROUND: Primary hyperoxaluria type 2 is a rare monogenic disorder inherited in an autosomal recessive pattern. It results from the absence of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). As a consequence of deficient enzyme activity, excessive amounts of oxalate and L-glycerate are excreted in the urine, and are a source for the formation of calcium oxalate stones that result in recurrent nephrolithiasis and less frequently nephrocalcinosis. CASE PRESENTATION: We report a case of a 10-month-old patient diagnosed with urolithiasis. Screening of inborn errors of metabolism, including the performance of GC/MS urine organic acid profiling and HPLC amino acid profiling, showed abnormalities, which suggested deficiency of GRHPR enzyme. Additional metabolic disturbances observed in the patient led us to seek other genetic determinants and the elucidation of these findings. Besides the elevated excretion of 3-OH-butyrate, adipic acid, which are typical marks of ketosis, other metabolites such as 3-aminoisobutyric acid, 3-hydroxyisobutyric acid, 3-hydroxypropionic acid and 2-ethyl-3-hydroxypropionic acids were observed in increased amounts in the urine. Direct sequencing of the GRHPR gene revealed novel mutation, described for the first time in this article c.454dup (p.Thr152Asnfs*39) in homozygous form. The frequent nucleotide variants were found in AGXT2 gene. CONCLUSIONS: The study presents metabolomic and molecular-genetic findings in a patient with PH2. Mutation analysis broadens the allelic spectrum of the GRHPR gene to include a novel c.454dup mutation that causes the truncation of the GRHPR protein and loss of its two functional domains. We also evaluated whether nucleotide variants in the AGXT2 gene could influence the biochemical profile in PH2 and the overproduction of metabolites, especially in ketosis. We suppose that some metabolomic changes might be explained by the inhibition of the MMSADH enzyme by metabolites that increase as a consequence of GRHPR and AGXT2 enzyme deficiency. Several facts support an assumption that catabolic conditions in our patient could worsen the degree of hyperoxaluria and glyceric aciduria as a consequence of the elevated production of free amino acids and their intermediary products.


Asunto(s)
Oxidorreductasas de Alcohol/deficiencia , Oxidorreductasas de Alcohol/genética , Hiperoxaluria Primaria/genética , Oxidorreductasas de Alcohol/metabolismo , Ácidos Aminoisobutíricos/orina , Análisis Mutacional de ADN , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Hidroxibutiratos/orina , Hiperoxaluria Primaria/diagnóstico , Lactante , Ácido Láctico/análogos & derivados , Ácido Láctico/orina , Urolitiasis/diagnóstico , Urolitiasis/genética , Valeratos/orina
11.
Semin Thromb Hemost ; 42(5): 550-62, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27235830

RESUMEN

UNLABELLED: We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born between January 1997 and October 2015, 59 were eligible for evaluation; 50 and 9 were treated with > 20 exposure days (ED) of plasma-derived FVIII (pdFVIII) and recombinant FVIII (rFVIII) products, respectively. In the entire group 13/59 (22%) PUPs developed inhibitors; i.e. 7/50 (14%) and 6/9 (67%) treated with pdFVIII and rFVIII, respectively. Univariate analysis of inhibitor risk factors in patient groups with and without inhibitors showed the rFVIII and serious/recurrent infections within the first 50 EDs to be associated with inhibitor development (OR of 12.3 [95% CI 2.48-60.83; p = 0.002] and 5.0; [95% CI 1.16-21.9; p = 0.03), respectively]). Also, in multivariate Cox regression analysis, peak treatment ≥ 5 EDs reached statistical significance. The hazard ratio (HR) was 7.15 (95% CI 1.65-31.36) p = 0.0086 for rFVIII and 4.38 (95% CI 1.02-18.67) p = 0.046 for intensive treatment. Between 1993 and 2015, 21 immune tolerance inductions (ITIs) in 19 inhibitor patients were performed in the two largest hemophilia centers in Slovakia. In all but one ITI courses pdFVIII containing von Willebrand factor (FVIII/VWF) was used with preferred use of high-dose ITI (HD ITI) in high responders (HRs). Complete or partial success was achieved in 17/19 (89.5%) patients. Evaluating only the patients who already completed ITI, the success rate was even higher (15/16; 94%), including 7/7 low responders and 8/9 HR. CONCLUSION: Our national prospective study comprising entire group of PUPs with severe hemophilia A showed higher incidence of inhibitors in patients treated with rFVIII and those with intensive therapy within first 50 EDs. However, our experience is limited to small numbers of patients; thus, our results must be interpreted cautiously. High success rate of the ITI in our inhibitor patients has been achieved with FVIII/VWF concentrates and preferred use of HD ITI in HR patients.


Asunto(s)
Inhibidores de Factor de Coagulación Sanguínea/sangre , Factor VIII/administración & dosificación , Factor VIII/efectos adversos , Hemofilia A/sangre , Hemofilia A/tratamiento farmacológico , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Factores de Riesgo , Índice de Severidad de la Enfermedad , Eslovaquia
12.
Mol Biol Rep ; 42(9): 1359-63, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26094004

RESUMEN

The peroxisomal biogenesis disorders are autosomal recessive diseases morphologically characterised by lacking peroxisomes, biochemically by generalised deficiency of peroxisomal constituent and clinically manifested by serious health problems. Genes involved in the peroxisomal biogenesis are defined as the PEX genes encoding proteins called the peroxins. These peroxins are required for function in assembly of the peroxisomal membrane or in import of the enzymes into the peroxisomes. In this study we present a full overview of the clinical presentation, biochemical and molecular data of patient with Zellweger syndrome from Slovakia. We investigated biochemical metabolites using gas chromatography/mass spectrometry. The presence of causal ins/del mutations we identified by a Sanger sequencing and RFLP. We reported that the patient was a compound heterozygote for mutations in the gene PEX12: a 2-bp insertion (c.767_768dupAT) and a 2-bp deletion (c.887_888delTC). The first one mentioned is a novel mutation, which has not been reported before. Both mutations create a frameshift of the open reading frame which result a premature STOP codon and generate a complete loss of the C-terminal RING finger domain that is crucial for the correct import of proteins into peroxisomes. We found causal mutations responsible for a severe phenotype, and moreover we noted a novel mutation c.767_768dupAT that has not been reported before. The presence of mutations was studied in all family members, and the resulting data were successfully utilized for prenatal diagnosis.


Asunto(s)
Mutación INDEL , Proteínas de la Membrana/genética , Síndrome de Zellweger/genética , Análisis Mutacional de ADN , Resultado Fatal , Heterocigoto , Humanos , Recién Nacido , Masculino , Proteínas de la Membrana/metabolismo , Linaje , Dominios RING Finger , Eslovaquia , Población Blanca/genética
13.
Eur J Pharmacol ; 721(1-3): 178-84, 2013 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-24113525

RESUMEN

The aim of our study was to estimate cytostatic/cytotoxic activity of the copper(II) Schiff base complex of the composition [Cu(N-salicylidene-l-glutamato)(H2O)2]·H2O, further Cu(SG-L)H2O, against human colon carcinoma cell line HT-29, as well as to determine type of cell death and to find out the molecular mechanism of apoptosis induced by this complex. Two highest concentrations (50, 100 µmol/l) of the complex showed a strong cytotoxic activity against human colon carcinoma cells HT-29 after 72 h of influence. Other concentrations had a cytostatic activity. Unchelated copper(II) ions and free ligands had no effect on the cell growth. Cu(SG-L)H2O preferentially reduced cancer cell viability compared to healthy cells (NIH-3T3). Cu(SG-L)H2O induced apoptosis of cells HT-29 at all concentrations used (1-100 µmol/l) after 48 h of influence. Apoptosis was carried out by the mitochondrial pathway with active caspases 3 and 9. By the spin-trapping technique combined with electron paramagnetic resonance we found that our complex is photochemically stable in aqueous systems and does not exhibit radical-scavenging activity when 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate) cation radical was used as an oxidant. The complex exhibits a strong prooxidant property in the initial stages of thermal decomposition of K2S2O8 in water solutions leading to the massive production of (·)OH radicals. Therefore, this complex could strongly participate in anticancer action via a free radical mechanism.


Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Antioxidantes/química , Antioxidantes/farmacología , Compuestos Organometálicos/química , Compuestos Organometálicos/farmacología , Caspasas/metabolismo , Muerte Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células HT29 , Humanos , Enlace de Hidrógeno , Bases de Schiff/química , Relación Estructura-Actividad
14.
Lipids Health Dis ; 12: 126, 2013 Aug 21.
Artículo en Inglés | MEDLINE | ID: mdl-23961716

RESUMEN

BACKGROUND: Statins (HMG-CoA reductase inhibitors) represent a major class of compounds for the treatment of hypercholesterolemia due to their ability to inhibit de novo cholesterol synthesis. In addition to their hypolipidemic effects, chemoprotective properties have been attributed to statins as well. These effects involve multiple mechanisms, which, however, are not known in detail. The aim of our study was to assess in non-malignant as well as cancer cells the impact of simvastatin on the amount of cytosolic lipid droplets (LDs) implicated in many biological processes including proliferation, inflammation, carcinogenesis, apoptosis, necrosis or growth arrest. METHODS: Human embryonic kidney cells HEK-293T and human pancreatic cancer cells MiaPaCa-2 were treated with simvastatin (6 and 12 µM) for 24 and 48 hours respectively. Neutral lipid probe Nile Red was used for detection of LDs by fluorescence microscopy. Cellular cholesterol content was determined by HPLC. Changes in expression of genes related to lipid metabolism in simvastatin-treated MiaPaCa-2 cells were examined by DNA microarray analysis. Validation of gene expression changes was performed using quantitative RT-PCR. RESULTS: The treatment of the cells with simvastatin increased their intracellular content of LDs in both non-malignant as well as cancer cells, partially due to the uptake of cholesterol and triacylglyceroles from medium; but in particular, due to enhanced synthesis of triacylglyceroles as proved by significant overexpression of genes related to de novo synthesis of triacylglyceroles and phospholipids. In addition, simvastatin also markedly influenced expression of genes directly affecting cell proliferation and signaling. CONCLUSIONS: Simvastatin treatment led to accumulation of cytosolic LDs within the examined cells, a phenomenon which might contribute to the antiproliferative effects of statins.


Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Gotas Lipídicas/efectos de los fármacos , Neoplasias Pancreáticas/tratamiento farmacológico , Simvastatina/farmacología , Línea Celular Tumoral/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Proliferación Celular/genética , Colesterol/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Células HEK293/efectos de los fármacos , Humanos , Gotas Lipídicas/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Metabolismo de los Lípidos/genética , Neoplasias Pancreáticas/metabolismo
15.
Exp Biol Med (Maywood) ; 237(1): 10-7, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22156044

RESUMEN

Damage or loss of articular cartilage as a consequence of congenital anomaly, degenerative joint disease or injury leads to progressive debilitation, which has a negative impact on the quality of life of affected individuals in all age groups. Classical surgical techniques for hyaline cartilage reparation are frequently insufficient and in many cases it is not possible to obtain the expected results. For this reason, researchers and surgeons are forced to find a method to induce complete cartilage repair. Recently, the advent of tissue engineering has provided alternative possibilities for the treatment of these patients by application of cell-based therapy (e.g. chondrocytes and adult stem cells) combined with synthetic substitutes of the extracellular matrix and bioactive factors to prepare functional replacement of hyaline cartilage. This communication is aimed at a brief review of the current status of cartilage tissue engineering and recent advances in the field.


Asunto(s)
Enfermedades de los Cartílagos/terapia , Cartílago Articular , Ingeniería de Tejidos , Andamios del Tejido , Células Madre Adultas/citología , Células Madre Adultas/fisiología , Animales , Cartílago Articular/citología , Cartílago Articular/patología , Cartílago Articular/fisiología , Diferenciación Celular , Condrocitos/citología , Condrocitos/fisiología , Condrocitos/trasplante , Matriz Extracelular/fisiología , Humanos , Péptidos y Proteínas de Señalización Intercelular/farmacología , Péptidos y Proteínas de Señalización Intercelular/fisiología , Artropatías/terapia , Articulaciones/lesiones , Articulaciones/cirugía , Ingeniería de Tejidos/métodos
16.
Gen Physiol Biophys ; 29(4): 362-72, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21156999

RESUMEN

Molecular biology seems to bring more convincing markers for the detection of prostate cancer as well as the development of metastases than immunohistochemistry. The main goal of present work was to detect the expression of prostate specific antigen (PSA) and prostate-specific membrane antigen (PSM) genes in the micrometastases by the RT-PCR to assess the progression of prostate cancer. We analyzed 50 patients: 28 patients with clinically localized or locally advanced prostate cancer who underwent radical prostatectomy, 7 patients with clinically proven metastases, 8 patients with benign prostatic hyperplasia, and 7 healthy young men. The results of RT-PCR in the first group of 28 patients varied, however, they were in good correlation with the health status of the patients. Positive results of PSA and notably for PSM were good predictors of beginning metastasing process. Seven patients with metastatic disease had positive RT-PCR results both for PSA and PSM. All of the patients with benign prostatic hyperplasia and healthy young men had negative RT-PCR results for PSA and PSM. The study showed that positive RT-PCR results for PSA and especially for PSM correlated well with the progression of the disease and negative results reflected good health status of the patients.


Asunto(s)
Progresión de la Enfermedad , Estadificación de Neoplasias/métodos , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Anciano , Anciano de 80 o más Años , Antígenos de Superficie/genética , Regulación Neoplásica de la Expresión Génica , Glutamato Carboxipeptidasa II/genética , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Antígeno Prostático Específico/genética , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/cirugía , Reproducibilidad de los Resultados
17.
Neuro Endocrinol Lett ; 31(4): 474-6, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20802453

RESUMEN

OBJECTIVE: The incidence of carcinoma of endometrium in younger patients has increased tendency. Experimental data support that mutation of tumor suppressor gene TP53 plays an important role in endometrial carcinogenesis MATERIAL AND METHODS: Exons 2-11 of the gene TP53 into tissues of endometrial carcinoma and precancerous lesions were analyzed by DNA sequencing and restriction analysis. RESULTS: A polymorphism CCC/CGC at codon 72 was identified in exon 4 of TP53 gene of all precancerous lesions and carcinomas of endometrium. CONCLUSION: Our results also suggest presence of endometrial glandular dysplasia or serous histological type of endometrial carcinoma into examined samples. Given the course and prognosis of serous endometrial carcinoma, it is necessary and useful to identify this type of cancer in the mixed types of endometrial carcinomas. DNA analysis has potential to make diagnostic process more specific and affect to adjuvant therapy and survival of patients.


Asunto(s)
Carcinoma/genética , Neoplasias Endometriales/genética , Proteína p53 Supresora de Tumor/genética , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma/patología , Neoplasias Endometriales/patología , Femenino , Humanos , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Polimorfismo Genético
19.
Med Sci Monit ; 15(9): CS143-7, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19721404

RESUMEN

BACKGROUND: It is well known that the frequency of multiple gestation increases after in vitro fertilization in which more than one embryo is transferred. The aim is to report an octuplet pregnancy following intracytoplasmic sperm injection and cryo embryo transfer. CASE REPORT: A 31-year-old woman and her 35-year-old husband, both Caucasian, complained of primary infertility. The intracytoplasmic sperm injection and cryo embryo transfer procedure was recommended as treatment. Ovarian stimulation was performed using recombinant follicle-stimulating hormone and human menopausal gonadotropin. Two embryos were transferred to the uterus. This fertilization cycle was unsuccessful. Three months later, cryo embryo transfer of two frozen/thawed embryos was performed, which resulted in pathological monozygotic octuplet anembryonic pregnancy. Two, and later eight, empty sacs were detected by sonographic examination. Cytogenetic examination revealed normal male karyotype. DNA analysis confirmed identical polymorphisms in all the gestation sacs, i.e. a monozygotic origin of all eight sacs. CONCLUSIONS: We report a rare case of octuplet pregnancy after intracytoplasmic sperm injection and cryo embryo transfer.


Asunto(s)
Criopreservación , Transferencia de Embrión , Embarazo Múltiple , Inyecciones de Esperma Intracitoplasmáticas , Adulto , Femenino , Humanos , Cariotipificación , Masculino , Polimorfismo Genético , Embarazo
20.
Gen Physiol Biophys ; 28(1): 56-62, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19390137

RESUMEN

In the present work, the human bone marrow and adipose tissue-derived mesenchymal stem cells (MSCs) were isolated and expanded under in vitro condition. After their phenotypic analysis, the chondrogenic differentiation was induced by using of the three-dimensional culture system without supplementation of growth factors, and their chondrogenic potential was compared. Obtained results proved that both types of MSCs undergo the process of chondrogenic differentiation. Comparative analysis showed that chondrogenic potential of adipose tissue-derived MSCs was slightly decreased in comparison with bone marrow-derived MSCs. However, both evaluated MSCs may play important role in the cartilage tissue engineering.


Asunto(s)
Tejido Adiposo/fisiología , Células Madre Adultas/fisiología , Células de la Médula Ósea/fisiología , Condrogénesis/fisiología , Células Madre Mesenquimatosas/fisiología , Tejido Adiposo/citología , Adulto , Células Madre Adultas/citología , Antígenos CD/metabolismo , Células de la Médula Ósea/citología , Técnicas de Cultivo de Célula , Células Cultivadas , Colágeno Tipo II/metabolismo , Antígenos HLA/metabolismo , Humanos , Inmunohistoquímica , Masculino , Células Madre Mesenquimatosas/citología , Fenotipo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA